A fearless and fervent local campaigner died while on holiday with his wife in Florida. Glyn Dale was one of hundreds of ...

The FDA has approved Nucala (mepolizumab) for the add-on maintenance treatment of patients with inadequately controlled eosinophilic COPD.

Certain groups of physical multimorbidity may be associated with a higher risk of subsequent depression, according to a study.

Nucala's approval offers hope for uncontrolled COPD. This new drug reduces flare-ups, a key benefit for Black Americans.

Long-term health care utilization is greater among patients with COPD who have tested positive for COVID-19 and are unvaccinated.

Patients with COPD and established cardiovascular disease have more MACEs and seek less preventive cardiac care than patients with CVD alone.

In light of the significant drop in Regeneron’s stock price, a natural question emerges: is REGN now a viable buying ...

For over a decade, Sidney resident Leo Levasseur has been a vocal advocate for banning the sale of cigarettes in British ...

Machine learning models using data from digital inhalers can successfully predict COPD exacerbations up to 5 days in advance.

Regeneron’s stock is having its worst day in 14 years after the failure of late-stage trial of its COPD treatment, after ...

Facing erosion of its mighty Eylea (aflibercept) franchise and near-term loss of exclusivity with Dupixent (dupilumab), Regeneron Pharmaceuticals Inc. took a blow as one of two phase III trials with ...

Regeneron and Sanofi face setbacks as itepekimab stumbles in phase 3. Click here to read why I believe SNY and REGN stocks ...